Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (101-110 of 211) with videos related to

Pageof 22
Sort By:
JCO Precision Oncology|December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted TherapiesJordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
JCO Precision Oncology|September 4, 2024
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown PrimaryHarry E Fuentes Bayne, Pashtoon M Kasi, Li Ma, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Ian W Flinn, David R Spigel, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancerDavid S Ettinger, Robert Jotte, Paul Lorigan, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.
Pageof 22

Showing results (101-110 of 211) with videos related to

Sort By:
Pageof 22
JCO Precision Oncology|December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted TherapiesJordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
JCO Precision Oncology|September 4, 2024
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown PrimaryHarry E Fuentes Bayne, Pashtoon M Kasi, Li Ma, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 13, 2010
Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Ian W Flinn, David R Spigel, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancerDavid S Ettinger, Robert Jotte, Paul Lorigan, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.
Pageof 22